key: cord-0037511-kj4z16zf
authors: Hemmige, Vagish; Liles, W. Conrad; Pitrak, David L.
title: Use of Filgrastim (r-metHuG-CSF) in Human Immunodeficiency Virus Infection
date: 2011-07-11
journal: Twenty Years of G-CSF
DOI: 10.1007/978-3-0348-0218-5_18
sha: 8a7d54394ad39a74311a889c6fb4f6ab55a10015
doc_id: 37511
cord_uid: kj4z16zf

In 2008, an estimated 33.4 million individuals worldwide were infected with the human immunodeficiency virus (HIV) [1]. Only a few years ago, infection with HIV almost invariably culminated in the development of the acquired immunodeficiency syndrome (AIDS), characterized by severe depletion of CD4(+) lymphocytes leading to derangements predominantly affecting cell-mediated immunity, but affecting humoral immunity as well [2]. In the later stages of AIDS, neutropenia and neutrophil functional deficits were common sequelae of HIV infection, other opportunistic infections, or HIV- or opportunistic infection-related treatment [3]. The care of the HIV-infected patient was palliative in nature, and the possibility that use of filgrastim (rHuG-CSF) might extend survival in late-stage AIDS patients with severe neutropenia or severe opportunistic infections, or might be a treatment for HIV infection itself, was explored [4]. Subsequently, however, the development of protease inhibitors and the widespread adoption of their use in multidrug regimens of highly active antiretroviral therapy (HAART) revolutionized the care of HIV-infected patients, and the number of patients dying from HIV decreased dramatically [5].

comorbid conditions and increased rates of cardiovascular [7] and oncologic death [8] . However, despite the widespread availability of HAART in the developed world, patients still present with late-stage AIDS and its attendant complications, including neutropenia, because of late diagnosis of HIV [9] or progression of HIV infection due to nonadherence to HAART [10] . Furthermore, patients with HIV face an increased risk of malignancy and the subsequent need to be treated with cytotoxic chemotherapy [11] . Accordingly, filgrastim has continued to play a role in the management of selected patients with HIV.

From the earliest days of the AIDS pandemic, neutropenia was identified as a consequence of HIV infection. In 1987, an absolute neutrophil count (ANC) of <2.0 Â 10 9 /L was reported in 4 of 20 patients with clinically diagnosed AIDS and 15 of 59 with persistent generalized lymphadenopathy [12] . As this report predates the development of antibody testing for HIV, it was not possible to determine whether patients with persistent generalized lymphadenopathy were truly HIVinfected or not. No patient had an ANC <1.0 Â 10 9 /L in this report, although the same author had noted an ANC of 0.4 Â 10 9 /L in one patient in a case series of homosexual men with neutropenia in 1985 [13] .

Neutropenia is primarily a consequence of late-stage AIDS, with the mean CD4 + lymphocyte count during the first episode of neutropenia in one large study being 85 cells/mm 3 . However, 14% of patients with a neutropenic episode in this study were observed to have a CD4 + lymphocyte count >200 cells/mm 3 , and one patient's CD4 + lymphocyte count at the time of neutropenia was 858 cells/mm 3 [14] . It is worth noting that several case reports have associated neutropenia with acute HIV infection [15] [16] [17] [18] . Since most instances of acute HIV infection are unrecognized [19] , the true incidence of neutropenia associated with acute HIV infection remains unknown.

The epidemiology of neutropenia was examined in the Women's Interagency HIV Study, a prospective cohort study of 2,059 HIV-infected women enrolled in 1994 and 1995. In this cohort, 1,729 women had a documented ANC measured. It was observed that 7% of women were neutropenic at enrollment, which reflected the prevalence of neutropenia in the pre-HAART era, and that 31% of the study cohort experienced at least one episode of neutropenia (defined as a measured ANC <1.0 Â 10 9 /L) during the study. Low CD4 + lymphocyte count and high viral load, suggestive of progression of disease, were associated with the development of neutropenia [20] .

Neutropenia is often multifactorial in AIDS patients, with HIV itself, myelosuppressive drugs, opportunistic infections, and malignancy most frequently identified as the etiology. Although zidovudine is the most common antiretroviral associated with neutropenia, other nucleoside reverse transcriptase inhibitors have been implicated in drug-induced neutropenia as well [21] . Indinavir-induced neutropenia has been reported [22] , as has neutropenia exacerbated by efavirenz [23] .

Noteworthy also are case reports of patients receiving chemotherapy concomitantly with antiretroviral regimens containing ritonavir, a potent inhibitor of the CYP450 system, and subsequently developing neutropenia due to increased concentrations of chemotherapeutic agents [24] [25] [26] . Other prophylactic agents including dapsone [27] , antifungals, and beta-lactam antibiotics [28] have also been reported to cause neutropenia. Disseminated infections with bone marrow involvement caused by fungal (e.g., endemic mycoses, cryptococcosis) [29] , mycobacterial (e.g., tuberculosis or Mycobacterium avium complex), protozoal (e.g., leishmaniasis), or viral (e.g., cytomegaloviral) pathogens have been identified as contributors to HIVassociated neutropenia [30] . Finally, infiltration of bone marrow with lymphoma is not infrequently a cause of HIV-associated neutropenia [31] , and this possibility should be considered before ascribing neutropenia to medications alone.

The proportion of neutropenic episodes attributable to each of the above causes depends on the patient population. In one Italian study including 81 neutropenic patients in the pre-HAART era, most of whom were intravenous drug users, neutropenia was attributed to HIV itself in 18.5% of the patients, to infiltration of bone marrow with lymphoma or infection in 24.6% of patients, and drugs in 56.7%. Of patients with drug-induced neutropenia, zidovudine was a contributor to 48.2% of cases, chemotherapy to 21.3% of cases, trimethoprim-sulfamethoxazole to 18 .7%, amphotericin B to 17.5%, ganciclovir to 13.6%, pyrimethamine to 11.1%, and dapsone to 6.4% of cases [32] . In a different study, zidovudine therapy was a contributing factor to neutropenia in 51% of patients, trimethoprim-sulphamethoxazole treatment in 45% of patients, ganciclovir therapy in 18% of patients, and cytotoxic chemotherapy in 11.3% of patients; neutropenia was attributed to lymphoma in 6.5% of cases and HIV infection itself in 1.6% of patients [31] .

The epidemiology of neutropenia in HIV patients has drastically changed with the advent of HAART. HAART prevents progression of HIV, and was found to prevent the development of neutropenia in the Women's Interagency HIV study cohort [20] . Furthermore, HAART itself is an effective long-term treatment for HIV-associated neutropenia [33, 34] . In addition, the decreased dose of zidovudine employed as part of HAART regimens may be less likely to cause neutropenia than the higher dose used in the pre-HAART era. One study where patients were routinely converted from stavudine to zidovudine after 6 months of HAART therapy reported that only 7.7% of patients developed an ANC <0.75 Â 10 9 /L [33] , and a similar conversion study of 78 HIV-infected children reported that only 6% developed an ANC <1.0 Â 10 9 /L. In the latter study, no individual's ANC decreased to <0.75 Â 10 9 /L [34] .

In addition to neutropenia, there are functional defects of neutrophils, as well as monocytes and macrophages, in HIV infection and other lentivirus infections. These defects are not unique to HIV infection, and a number of viral infections have been associated with impaired neutrophil function [35] . A wide range of functional defects exist, including defects in chemotaxis, phagocytosis, the respiratory (oxidative) burst, and microbicidal capacity [36] [37] [38] [39] [40] [41] . Neutrophils isolated from HIV-infected patients have a profound defect in chemotaxis in response to interleukin (IL)-8 and bacterial chemoattractant peptides, such as f-met-leu-phe (fMLP), and the degree of impairment correlates with the degree of CD4 + T-cell depletion. Other physiologic functions related to recruitment to sites of infection, rolling, adhesion, and emigration are also affected, as shown in a feline leukemia virus (FIV) infection model. Evidence that this may be due to a maturation defect is decreased granularity of neutrophils from the blood and bone marrow of FIVinfected animals. The results of different studies of neutrophil function in HIV infection are at times conflicting and can be explained by different assays, different conditions, and differences in the patient populations studied. The most important clinical variable is the stage of HIV disease as evidenced by absolute CD4 + T-cell count.

The respiratory burst is a very important part of the microbial killing by neutrophils, generating superoxide and other bactericidal reactive oxygen species. Our group previously examined the neutrophil respiratory burst by chemiluminescence in a cohort of 78 patients with HIV infection at different stages of disease [42] . Patients with HIV infection had altered oxidative metabolism in response to opsonin receptor-dependent stimulation with zymosan opsonized with purified human complement (C3bi) or immune globulin (IgG). Patients with early HIV infection with CD4 + lymphocyte counts >500 cells/mm 3 exhibited increased neutrophil chemiluminescence in response to opsonized zymosan compared with controls, while patients with advanced disease with low CD4 + lymphocyte counts showed significantly decreased chemiluminescence. Absolute CD4 + lymphocyte count was the only patient variable significantly correlated with opsonin-dependent neutrophil chemiluminscence activity according to multiple regression analysis. Despite a good correlation between ANC and CD4 + lymphocyte count (R ¼ 0.24; p ¼ 0.04), ANC was not an independent predictor of impaired neutrophil chemiluminescence by multiple regression analysis.

The pathophysiology of neutropenia and neutrophil dysfunction in HIV infection unrelated to drug therapy or secondary complications has been better elucidated in the past few years. A subset of neutropenic HIV-infected patients may have autoimmune neutropenia; however, this probably accounts for a small proportion of cases of neutropenia [13, 43] . A study of neutropenic children with HIV infection showed that while many children had circulating antineutrophil antibodies, the presence of these antibodies did not correlate with the ANC [44] .

The various immune abnormalities observed in HIV infection occur in the setting of immune systemic activation. There has been considerable interest in immune system activation occurring as a result of T-cell depletion in gut-associated lymphoid tissue (GALT) with loss of mucosal barrier function, which results in translocation of lipopolysaccharide (LPS) and other bacterial products that activate the immune system [45] . A number of investigators have shown that neutrophils are activated in vivo throughout the course of HIV infection, even in the absence of any clinical signs of secondary infectious complications [46] . Early in the course of HIV infection in vivo, activation or priming may actually result in enhanced function. This in vivo activation continues throughout the course of HIV infection, but eventually the functional capacity of the neutrophil begins to decrease significantly. It should also be noted that immune system activation has been proposed as a mechanism for impaired neutrophil function in patients with chronic hepatitis B infection [47] .

Our studies of neutrophil chemiluminescence suggest that immune system activation may contribute to neutrophil dysfunction [42] . Maximum opsonin receptor expression (MOR) is achieved by exposing neutrophil to quantities of proinflammatory mediators (primers: fMLP, complement fragment C5a, and platelet-activating factor) to induce a maximal number of CD11b (C3bi receptor) and CD35 (C3b receptor or complement receptor 1) on the neutrophil surface. Priming may also enhance oxidative responses to a second stimulus by increasing the affinity of opsonin receptors for their particular ligand or enhancing intracellular signaling. Our experiments showed increases in the ratio of the chemiluminescence unprimed neutrophil at circulating opsonin receptor expression (COR) to chemiluminescence with MOR, i.e., an increased COR/MOR ratio. By whatever mechanism, neutrophils from HIV-infected patients behave as if they have been primed or activated by proinflammatory mediators in vivo. Opsonin receptor-independent NADPH-oxidase and myeloperoxidase activities, basal and stimulated, were significantly increased for HIV-infected patients, especially those with advanced disease with CD4 + lymphocyte count <200 cells/mm 3 . The increase in enzyme activities of NADPH-oxidase and myeloperoxidase may also be the result of in vivo activation. The decrease in myeloperoxidase activity for patients with very advanced HIV infection with CD4 + lymphocyte count <100 cells/mm 3 , although significantly higher than values seen in control subjects without HIV infection, may be due to degranulation resulting from in vivo activation. This chronic in vivo activation may lead to metabolic exhaustion or "burnout," and contributes to impaired neutrophil oxidative responses in HIV-infected patients at advanced stages of disease.

In vivo activation is not the only process that contributes to neutrophil dysfunction in HIV infection. Neutrophils isolated from patients with advanced HIV disease undergo accelerated apoptosis or programmed cell death. We studied apoptosis of neutrophils isolated from ten individuals with advanced HIV infection and seven control subjects [48] . Ex vivo apoptosis was examined morphologically by fluorescent microscopy after dual staining with acridine orange and ethidium bromide, fluorescent stains that intercalate DNA. Acridine orange stains the nucleus bright green and allows visualization of the nuclear chromatin pattern, while ethidium bromide identifies nonviable cells by staining the nucleus orange. Little apoptosis was evident immediately after isolation, but over time, apoptosis was observed and the proportion of apoptotic cells was significantly higher for the patients with advanced HIV infection at 3, 6, and 18 h (Fig. 1 ). Apoptotic cells eventually die, and at 18 h there was a significant decrease in viability for the HIV patient's neutrophils due to an increased number of nonviable, apoptotic cells. As neutrophils become apoptotic, they become functionally impaired, and the accelerated apoptosis of neutrophils may in part explain the impairment of neutrophil function seen in this patient population, as well as neutropenia. A number of possible mechanisms for accelerated apoptosis exist, including increased levels of proinflammatory mediators that may accelerate the process. Other mechanisms may also be involved, including direct effects of viral proteins. HIV protease can directly induce apoptosis of a variety of leukocyte populations [49] . Alternatively, growth factor deficiency could result in accelerated apoptosis.

Granulocyte precursors can be infected by HIV, and this may affect normal proliferation and development of neutrophils, but mature cells are not targets and express very little, if any, HIV [50] . Infection of bone marrow stromal cells may affect the microenvironment for myelopoiesis. Both HIV and cytomegalovirus (CMV) can infect bone marrow stromal cells and impair production of endogenous colony-stimulating factors such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) [51, 52] . Altered cytokine secretion may result in abnormal neutrophil maturation. G-CSF is a key growth factor important in maintaining the normal number of circulating neutrophils. Although several growth factors can stimulate myelopoiesis, studies of G-CSF-deficient knock-out mice indicate G-CSF is a cytokine necessary to maintain normal neutrophil counts [53] . Evidence is accumulating that HIV infection results in a state of endogenous G-CSF deficiency [54, 55] . Patients with HIV have lower serum levels of endogenous G-CSF for a given degree of neutropenia compared with patients with neutropenia from other etiologies, such as aplastic anemia and cancer chemotherapy. The low levels of G-CSF may not only impair myelopoiesis and The principle way growth factors cause clonal expansion of different bone marrow precursors is by inhibiting apoptosis of these cells [56] . Our data show that accelerated neutrophil apoptosis in HIV infection is reversible in vitro and ex vivo in patients receiving filgrastim [48, 57] .

Why should a decrease in growth factor(s) required for neutrophil maturation occur in a disease characterized by abnormal cell-mediated immunity? The source of G-CSF, directly or indirectly, is activated T-cells, monocytes, and macrophages, all targets for HIV infection. Depletion or dysfunction of these cells as a result of HIV infection may result in decreased production of G-CSF that is required to support normal granulopoiesis and/or neutrophilic responses to infection. We previously reported that peripheral blood mononuclear cells (PBMC) isolated from patients with AIDS produce significantly less G-CSF in response to a challenge with LPS [54] . Local G-CSF production by bone marrow stromal cells is likely to be very important in granulopoiesis, and there is a decreased G-CSF response by bone marrow stromal cells from patients with HIV infection ex vivo in response to IL-1 and LPS [51] .

More is known about how CD4 + T-helper cells recruit and activate a wide variety of cell types, including macrophages, mast cells, neutrophils, eosinophils, and basophils, in addition to adaptive immune effector cells. Several different types of CD4 + T-cells have been described that differentiate from naïve CD4 + T-cells [55] . In addition to Th1 and Th2 cells, we now recognize regulatory T-cells (Treg) [58] . These cells not only are involved in immunosuppression, but also can differentiate into effector T-cells. More has also been discovered about the interactions between phagocytic cells and T-cells. The Th17 pathway has been characterized [59] . Th17 cells have been classified as a new lineage, distinct from Th1, Th2, and Treg cells. T17 cells develop as a result of a unique set of cytokines secreted by effector cells of the innate immune system (e.g., neutrophils) and additive effects of IL-1b and tumor-necrosis factor (TNF)-a. Transforming growth factor (TGF)-b and IL-6 are crucial factors in the generation of Th17 cells from naive T-cells. The functional capacity of Th17 cells depends on the additional cytokines IL-23 and IL-1.

Th17 cells are characterized by production of the proinflammatory cytokines IL-17A, IL-17F, IL-22, and IL-26. The activity of IL-17A and IL-17F is defined by induction of increased production of a number of proinflammatory mediators, including IL-1, IL-6, CXC chemokines, TNF-a, G-CSF, and GM-CSF by epithelial and endothelial cells, macrophages, and other stromal cells. IL-17A also promotes stem-cell factor (SCF)-and G-CSF-mediated granulopoiesis [60] . It has been controversial as to whether or not neutrophils directly respond to IL-17A or IL-17F, but the downstream production of cytokines induced by IL-17A and IL-17F leads to granulopoiesis, neutrophil recruitment, and neutrophil activation. Substantial evidence exists of cross-talk between neutrophils and Th17 CD4 + T-cells [61] . Purified human neutrophils produce chemokines that attract Th1 and Th17 cells, while Th17 cells produce CXCL8, a potent chemoattractant for neutrophils.

Th17 cells are important in host defense against infections caused by both intracellular pathogens, such as listeriosis, salmonellosis, cryptococcosis, leishmaniasis, and tularemia, and a variety of extracellular bacterial and fungal pathogens. The role of Th17 cells in specific infections is not completely understood and, in some infections such as invasive aspergillosis, the data are conflicting. It appears, however, that Th17 cells are very important for mucosal host defense against oral candidiasis, mainly through the recruitment of neutrophils, and may also be important in disseminated disease [62] . Th17 cells are also involved in the response to Staphylococcus aureus infection [63] .

Th17 cells express CD4, so it is not surprising that dysfunction and depletion of Th17 cells occur in HIV infection. Th17 cells are efficiently infected by HIV-1 in vitro [64] , which may help explain the broad range of bacterial and fungal pathogens, particularly extracellular pathogens, that infect patients with HIV. CD4+IL-17+ populations are greatly reduced in antiretroviral-naive HIV-infected patients compared to HIV-negative controls, but this subset is greatly increased after the initiation of HAART, while IFN-a T-cells (Th1) are unchanged [65] . Depletion of Th17 cells in the gut has been associated with decreased microbial barrier function of the gut and persistent immune activation due to gut translocation [66] . Other studies have even shown a decrease in TH17 cells and the Th17:Th1 ratio with preferential depletion of Th17 cells from GALT within weeks of simian immunodeficiency virus (SIV) infection in macaques [67] .

The cross-talk between Th17 cells and neutrophils and other phagocytic cells of the innate immune system may explain previous observations that rHuG-CSF may be of potential benefit for immune reconstitution in HIV infection. Previously, our group was part of a study that demonstrated that rHuG-CSF can restore IL-2 production in the blood of HIV-infected individuals [68] . At that time, it was unknown how rHuG-CSF affected T-cell function or production of a lymphocyte growth factor. In retrospect, neutrophil activation may lead to IL-6 release, subsequent Th17 differentiation, and IL-17 production. An inverse relationship exists between Treg and Th17 cells, so an increase in Th17-inducing cytokines may lead to a decrease in Tregs that mediate immunosuppression. Furthermore, T-cells are not only the source but also the target of IL-17. IL-17 can modulate Th1 cell polarization both in vitro and in vivo by directly acting on CD4 + T-cells [69] . Overall, however, the effects of rHuG-CSF on CD4 + lymphocyte counts have been variable [70, 71] .

Initial reports in the pre-HAART era suggested that the risk of infection in patients with HIV-associated neutropenia was less than the risk of infection in patients with neutropenia due to chemotherapy or hematologic malignancy, a fact attributed to, among other factors, the lack of mucosal injury in neutropenia not due to cytotoxic chemotherapy and the relatively mild nature of HIV-associated neutropenia compared to neutropenia associated with hematologic malignancy or cytotoxic chemotherapy. Farber et al., in one of the first studies to examine the risk of infection, retrospectively examined the records of 30 HIV-infected patients with ANC <1.0 Â 10 9 /L and CD4 + lymphocyte count <200 cells/mm 3 , comparing infection rates during neutropenic periods and non-neutropenic periods and comparing infection rates in these patients with 37 patients with hematologic malignancies as controls. In that study, no difference was found between infection rates in HIV patients during neutropenic periods compared with non-neutropenic periods [72] . Piliero et al., in reviewing blood culture data from 38 HIV-infected patients with ANC <0.5 Â 10 9 /L and 1,071 non-neutropenic HIV patients, found that the presence of a central venous catheter, but not neutropenia, was a risk factor for positive blood cultures in a multiple logistic regression model [73] .

A number of subsequent studies, however, have suggested that HIV-associated neutropenia is associated with an increased risk of infection. Shaunik and Bartlett, in an era when zidovudine monotherapy dosed at 1,200 mg/day was the standard of care for HIV treatment (compared with the dose of 600 mg/day used in current HAART regimens), found in a study of 30 patients that an ANC <0.5 Â 10 9 /L was associated with an incidence of bacterial infection that was 600% higher than the incidence observed when ANC was >1.0 Â 10 9 /L [74] . Keizer et al. performed a case-control study comparing 29 HIV-infected patients followed from 1991 to 1993 with two consecutive measured ANC <1.0 Â 10 9 /L with 29 HIV-infected controls without history of neutropenia matched for age, sex, CD4 + lymphocyte count, and month of entry into the clinic. An incidence of 12.6 episodes of bacteremia per 100 patient-months was observed in the patients with a history of neutropenia compared with an incidence of 0.87 episodes of bacteremia per 100 patient-months observed in the controls, a statistically significant difference (p ¼ 0.0027). In a multiple logistic regression model, neutropenia (OR ¼ 22.7) and the presence of a central venous catheter (OR ¼ 8.5) were independent predictors of the development of bacteremia [75] . Hambleton et al. compared the outcomes of HIV-infected inpatients who developed neutropenia after treatment with cytotoxic chemotherapy and those who developed neutropenia for other reasons from 1987 to 1990. In their cohort, few patients received filgrastim, and most patients were white men who had sex with men. They found no statistically significant difference in the rates of bacteremia or mortality between the two groups in both bivariate analysis and in multiple logistic regression models [70] . At the same center, but examining a different time period (1992-1993), Jacobsen et al. examined the rates of hospitalization for HIV-infected outpatients stratified by ANC, using ICD-9 codes to evaluate for the presence of infection. A total of 2047 outpatients were analyzed for this study. A progressive and statistically significant increase in the risk of hospitalization was noted as the nadir ANC decreased. The number of days hospitalized per 10,000 days of risk increased from 61 for patients whose ANC was always >0.5 Â 10 9 /L during the study period to 487 for patients with ANC nadir <0.3 Â 10 9 /L [71] .

Moore et al. performed a case-control study of patients followed from 1990 to 1994; 118 HIV-infected patients with a measured ANC <1.0 Â 10 9 /L were matched with HIV-infected non-neutropenic controls on the basis of history of intravenous drug use, CD4 + lymphocyte count, enrollment date in the clinic, and duration of follow-up. A statistically significant association between neutropenia and the development of a bacterial infection was observed. In an adjusted analysis, the relative risk for developing a bacterial infection was 2.33 times higher in patients with an ANC <1.0 Â 10 9 /L, and 7.92 times higher for patients with an ANC <0.5 Â 10 9 /L, compared with patients with an ANC >1.0 Â 10 9 /L; the incidence of bacterial infections was estimated as 3.5-4.5 per 100 patient-months of neutropenia [76] .

Eng et al. performed a retrospective cohort study examining the records of patients who received HIV care from 1990 to 1992. Of 930 patients, 85 experienced at least one episode of neutropenia, and of 12 patients with "severe" neutropenia (ANC <0.3 Â 10 9 /L), 3 experienced gram-negative bacteremia, compared with four episodes of gram-negative bacteremia in 61 patients with less severe neutropenia [77] .

Subsequently, Caperna et al. performed a retrospective cohort study examining patients who had at least two ANC measurements between 1991 and 1995. As the degree of neutropenia worsened, increases in the observed incidence of bacteremia with Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae were noted in this cohort of 1,645 patients [78] . A subsequent nested case-control study from the same cohort during the same time interval concluded that, adjusting for CD4 + lymphocyte count, clinical stage of HIV infection, and other confounders, a measured ANC <0.5 Â 10 9 /L conferred an eightfold increased risk of bacteremia with one of the three aforementioned pathogens [79] .

Tumbarello et al. retrospectively examined 9 years of patient records from a single center in Italy, comparing HIV-infected patients with bacteremia with both HIV nonbacteremic and HIV-uninfected bacteremic controls. In a multivariate analysis of HIV-infected patients, most of whom were intravenous drug users, low CD4 + lymphocyte count, presence of a central venous catheter, and ANC <1.0 Â 10 9 /L (OR 3.05; p ¼ 0.04) were independent risk factors for the development of bacteremia [32] .

Hermans et al., from a cohort of 1,870 HIV-infected patients seen at a Belgian HIV care center from 1982 to 1993, found 1,403 whose ANC had been measured at least once. From this sample, they identified 484 patients with episodes of neutropenia, defined in this study as a measured ANC <1.0 Â 10 9 /L. A history of neutropenia was associated with bacteremia or bacterial pneumonia. Subsequently, 177 neutropenic patients from this cohort were compared with 177 non-neutropenic controls matched for initial CD4 + lymphocyte count and duration of follow-up. Although, in unadjusted analysis, neutropenia was associated with increased odds of developing infection (OR 3.29), this association disappeared in a multiple logistic regression model which also included clinical stage of AIDS and hemoglobin concentration [80] .

Meynard et al. performed a single-institution prospective study that enrolled 62 HIV-infected patients with a measured ANC <1.0 Â 10 9 /L. In their study, a higher risk of infection was noted in neutropenic patients with malignancy compared with other neutropenic patients, and logistic regression modeling identified a history of neutropenia, the presence of a central venous catheter, and trough ANC as independent predictors of developing an infection [31] .

Kingdom with an ANC <1.0 Â 10 9 /L from 1994 to 1995, excluding 78 patients receiving cytotoxic chemotherapy. Bacteremias were documented in 21% of patients and were observed more commonly in patients with brief, profound neutropenias, rather than in patients with milder but more prolonged neutropenic episodes, and the degree of neutropenia correlated with the risk of infection [14] . A subsequent prospective study at the same center enrolled 87 patients in 1996 and 1997. No patients were receiving chemotherapy. Upon enrollment in the study, blood was sampled weekly to measure the duration of neutropenia. Filgrastim was only given for documented infection. The median duration of neutropenia was 13 days. Twelve subjects (17%) were diagnosed with neutropeniaassociated infection, in whom six were found to have infection serious enough to warrant filgrastim therapy, and four required hospital admission. All serious infections occurred in patients with ANC <0.5 Â 10 9 /L. A further four patients received filgrastim due to prolonged neutropenia [81] .

Most of the studies on the risk of infection in neutropenia were conducted in the pre-HAART era. Relatively fewer studies have attempted to assess the link between neutropenia and infection after the widespread implementation of HAART. In the Women's Interagency HIV study, which began in the pre-HAART era but extended through the development of HAART, it was observed that, independent of CD4 + lymphocyte count and viral load, which were strong predictors of mortality, the presence or absence of neutropenia was not predictive of mortality [20] .

Toure et al., in examining the incidence of neutropenia in a prospective cohort of 533 African patients over 6 years taking trimethoprim-sulfamethoxazole prophylaxis in a setting where HAART was available if indicated, found that 36% of patients had at least one measured ANC <1.0 Â 10 9 /L during the study, that developing neutropenia was associated with low initial CD4 + lymphocyte count, and that the adjusted hazard ratio of developing bacterial morbidity was 1.50 for patients with a history of neutropenia to that degree, but the overall likelihood of bacterial morbidity was low (36 patients overall) [82] .

Most of the preceding discussion has focused on bacterial infections. In patients with hematologic malignancy or in patients undergoing stem cell transplantation, invasive aspergillosis is a feared complication of the prolonged neutropenia that these patients experience [83] . Case reports and case series have noted the occurrence of aspergillosis in patients with advanced HIV [84] ; however, aspergillosis as a complication of neutropenia was an uncommon event in HIV-infected patients even before the advent of HAART [85] . Case series suggest that neutropenia or steroid use may predispose to invasive aspergillosis in HIV-infected patients [86, 87] . Mylonakis et al. reviewed 342 reported cases of aspergillosis in HIV-infected patients obtained by MEDLINE and AIDSLINE searches through 1997, and found that 93 patients were diagnosed with "definite" invasive aspergillosis, of whom 16 were reported to have an ANC <0.5 Â 10 9 /L [88] .

Since the beginning of the HIV epidemic, several dozen case reports, case series, and clinical trials have described the use of filgrastim and other formulations of rHuG-CSF in HIV-infected individuals without malignancy and have described outcomes (summarized in Table 1 ). Kimura et al. were the first to publish their experience, reporting on the use of rHuG-CSF in 14 Japanese patients, 11 of whom were neutropenic. The patient cohort primarily consisted of 12 patients with hemophilia, eight of whom demonstrated concurrent infection at the time of enrollment, and two of whom were experiencing fever of unknown origin. Patients were randomly assigned to receive 100 mg/m 2 or 200 mg/m 2 rHuG-CSF daily intravenously. The dose was subsequently titrated to maintain the ANC >3.0 Â 10 9 /L. A dose-dependent increase in ANC was observed in patients not receiving zidovudine, and escalation of rHuG-CSF dosage prevented the development of neutropenia in patients receiving zidovudine [89] .

Miles published the first reports specifically evaluating the benefit of filgrastim in neutropenic patients with HIV. In the first report, 13 patients were selected to receive filgrastim, which was initially dosed at 3 mg/kg daily with subsequent dose escalation until ANC >6.0 Â 10 9 /L. Once an adequate dose was established, it was maintained for 2 weeks; rHuEPO was subsequently given. Of the 13 patients selected, 1 died and 1 was removed from the study for noncompliance. In the other 11 patients, filgrastim therapy alone was associated with an increase in BFU-E (burst forming unit-erythron) levels, as well as a statistically significant mean hemoglobin increase of 1.04 g/dL [90] . Patients were then given zidovudine, dosed at either 1,000 or 1,500 mg/day. In the full analysis based on 22 recruited patients, 20 of whom were included in the final analysis, growth factors ensured that no patient needed to discontinue zidovudine therapy secondary to neutropenia, although eight patients developed transfusion dependence necessitating cessation of therapy [91] .

Bratt et al. were among the first to describe long-term outcomes from rHuG-CSF therapy, noting in their series of 17 patients that appropriate white blood cell counts could be maintained for up to 7 months in patients with initial counts <1.0 Â 10 9 /L [92] . Several small case series and small pilot studies were published in the ensuing years, but a pair of studies notable due to their size are the retrospective cohort studies reported by Grutzmeier and colleagues in 1996, reflecting treatment experience in the pre-HAART era. In one cohort of gay men with CD4 + lymphocyte counts <50 cells/mm 3 in Sweden, treatment with rHuG-CSF was initiated upon measuring a white blood cell count <1.0 Â 10 9 /L or ANC <0.5 Â 10 9 /L. Median survival in the 60 patients who received rHuG-CSF was 658 days, compared with a median survival of 511 days in the 104 patients who did not receive rHuG-CSF (p < 0.01). A similar analysis by the same authors performed on data from a similar cohort in Denmark found that the 60 patients who had received rHuG-CSF lived for ZDV zidovudine

Use of Filgrastim (r-metHuG-CSF) in Human Immunodeficiency Virus Infection a median of 248 days, compared with a median survival of 145 days in the 65 patients who did not receive rHuG-CSF [93] . Also notable for both its size and its prospective nature is the multicenter trial conducted by the G-CSF 92105 group and published in 1996. Patients were eligible if, on at least three occasions within a 2-week period, their measured ANC was found to be <1.0 Â 10 9 /L. Filgrastim dose was titrated to maintain ANC >2.0 Â 10 9 /L, a target obtained in 98% of patients. Patients received filgrastim for at least 28 days, but could receive it for a longer duration at the discretion of their physicians. The number of patients receiving what were considered to be the drugs most associated with neutropenia (zidovudine, trimethoprim-sulfamethoxazole, ganciclovir, and pyrimethamine) increased 20% over the course of the study [94] .

The results of the largest prospective randomized control trial to investigate the outcome of filgrastim administration to neutropenic patients with HIV were published by Kuritzkes et al. in 1998 . Of note, patients were accrued in the pre-HAART era. Eligibility requirements for this multicenter, nonblinded study included at least one measured ANC between 0.75 and 1.0 Â 10 9 /L, CD4 + lymphocyte count <200 cells/mm 3 , platelet count >50.0 Â 10 9 /L, Karnovsky score >50%, and life expectancy >6 months. Malignancy was the most notable exclusion criterion. In all, 258 patients were randomly assigned to daily, intermittent, or no filgrastim administration for 24 weeks, with filgrastim dose subsequently titrated to maintain white cell count in the 2.0-10.0 Â 10 9 /L range. Control patients receiving no filgrastim who developed an ANC <0.5 Â 10 9 /L were censored and subsequently re-randomized to one of the two treatment groups, an event which occurred in 18 patients. In all, 34.1% of patients who were assigned to receive no filgrastim developed the primary endpoint of severe neutropenia or death, compared with 12.8% of patients in the intermittent filgrastim group and 8.2% of patients in the daily filgrastim group. Patients who received filgrastim were 54% less likely than controls to develop a serious bacterial infection (p ¼ 0.005) [95] .

The most recent large study to examine the effect of filgrastim administration on outcomes in patients with HIV was the retrospective cohort study published by . This study was a retrospective analysis of data from several prospectively conducted studies of HIV-infected patients with CMV retinitis. Of note, significant heterogeneity in the use of filgrastim was present in the original trials. In an analysis made complex by the need to correct for the inherent biases of a retrospective analysis, filgrastim use was associated with a 56% reduction in death in a multivariate model (p < 0.01). Associations between filgrastim use and such outcomes as catheter-associated bacteremia and repeat bacterial infection were significant in unadjusted analysis but not after adjustment for confounders [96] .

Other interesting uses for rHuG-CSF which single reports have explored include the use of filgrastim as an adjunct to a tagged white blood cell scan in a neutropenic HIV-infected patient in the workup of postoperative fever [97] , and the use of filgrastim concomitantly with antimicrobials in the treatment of disseminated mycobacterial infection [98] .

The benefits of more widespread use of colony-stimulating factors in HIV-negative patients undergoing chemotherapy are now widely accepted, as demonstrated by recently written clinical guidelines which expand the criteria for their use [99] . This change in practice applies to HIV-infected patients as well. Although no randomized trial specifically has addressed the use of filgrastim in HIV-associated malignancy, several nonrandomized comparative studies looking at the benefits of adding rHuG-CSF to a chemotherapy regimen in patients with HIV-associated lymphoma have been published. In a pre-and postintervention trial where 65 HIV-infected patients with non-Hodgkin's lymphoma (NHL) either received a dose-reduced variant of the CHOP regimen (chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone) or full-dose CHOP augmented by filgrastim, grade 3 or 4 neutropenia occurred in fewer patients receiving full-dose CHOP with filgrastim (13% vs. 25%), a nonsignificant difference. The study was neither intended to nor powered to measure the effect of filgrastim independently [100] . A similar, nonrandomized study by Rossi found that HIV-positive patients receiving rHuG-CSF during chemotherapy were more likely than those who did not to receive full doses of chemotherapy and to receive cycles without delays, although the likelihood of complete response was actually lower in those who received rHuG-CSF [101] . A third study, also nonrandomized, compared the outcomes of HIV-positive patients undergoing chemotherapy for NHL, finding a decrease in mean duration of treatment delays between cycles from 9d to 4d (p ¼ 0.01). Again, however, mean duration of survival was worse in the group receiving rHuG-CSF, which also trended toward having more advanced HIV [102] . Further discussion of the role of rHuG-CSF in HIV-associated malignancies is beyond the scope of this chapter; a review of the use of hematopoietic growth factors in HIV-associated malignancies has been previously published [103] .

The most common side effect of filgrastim is bone pain, with headache, nausea, and vomiting also frequently reported [104] . Although generally safe, filgrastim usage in HIV patients has been associated with disseminated intravascular coagulation [105] , hepatitis, and pancreatitis [106] . In non-HIV patients, a review of case reports of adverse effects of filgrastim noted a number of rare adverse events, many of which were attributed to increased inflammation (ARDS, shock, worsening autoimmune disease) or leukostasis (arterial thrombosis or myocardial infarction, interstitial nephritis, bone marrow necrosis) [107] . Nevertheless, the adverse effect of filgrastim that serves as the biggest barrier to its use is its cost. However, filgrastim may be effective in HIV-infected patients at doses lower than those traditionally used for patients with chemotherapy-induced neutropenia [108] . One center developed a clinical pharmacist-driven protocol for dosing filgrastim in HIV-infected inpatients based on ANC; subsequently, the quarterly cost for filgrastim for the HIV service decreased from US$90,000 to US$22,000 [109] .

The incidence of neutropenia in HIV-infected patients has decreased with the advent of therapies that arrest and reverse the progression of AIDS. In the future, most patients with HIV who develop neutropenia will likely do so from oncologic disease and its treatment, not HIV itself. However, the inability of all HIV-infected patients to benefit from the advances in HIV treatment means that filgrastim will continue to play a role in the management of complications of advanced HIV and its treatment.

AIDS epidemic update

Pathogenic mechanisms of HIV disease

Neutropenia in patients infected with human immunodeficiency virus

Use of filgrastim (r-metHuG-CSF) in human immunodeficiency virus infection

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study

Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy

Cardiovascular disease in HIV infection

HIV infection is an independent risk factor for lung cancer

Late diagnosis of HIV infection: the role of age and sex

Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts !200 cells/ml

Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study

Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection

Immune neutropenia in homosexual men

A retrospective study of neutropenia in HIV disease

Immediate immunosuppression caused by acute HIV-1 infection: a fulminant multisystemic disease 2 days post infection

Severe transient neutropenia associated with acute human immunodeficiency virus type 1 infection

Autoimmune neutropenia and thrombocytopenia associated with development of antibodies to human immunodeficiency virus

Granulocytopenia secondary to acute infection with the human immunodeficiency virus

Clinical and epidemiologic features of primary HIV infection

Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study

A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV

Rash-associated severe neutropenia as a side-effect of indinavir in HIV postexposure prophylaxis

HIV-related neutropenia exacerbated by efavirenz

Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease

Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma

Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients

Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention

Incidence of {beta}-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis

Profound neutropenia in an HIV-infected man

Is it HIV? A handbook for health care providers

Frequency and risk factors of infectious complications in neutropenic patients infected with HIV

The impact of bacteraemia on HIV infection. Nine years experience in a large Italian University Hospital

Routine switch after 6 months from d4t to AZT containing antiretroviral therapy, at an outpatient HIV clinic in Phnom Penh, Cambodia. International AIDS society conference on HIV pathogenesis, treatment, and prevention

Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy

Depression of neutrophil function induced by viruses and its role in secondary microbial infections

Defective polymorphonuclear leukocyte chemotaxis in homosexual men with persistent lymph node syndrome

Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome

Blood monocyte and neutrophil functions in the acquired immune deficiency syndrome

Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation

Impairment of neutrophil bactericidal capacity in patients with AIDS

Depressed neutrophil superoxide production in human immunodeficiency virus infection

In vivo neutrophil activation and burnout in HIV infection

Neutrophil-associated antibodies and granulocytopenia in AIDS

Lack of relation of granulocyte antibodies (antineutrophil antibodies) to neutropenia in children with human immunodeficiency virus infection

Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection

Polymorphonuclear neutrophils from human immunodeficiency virus-infected patients show enhanced activation, diminished fMLPinduced L-selectin shedding, and an impaired oxidative burst after cytokine priming

A mechanism for liver cell injury in viral hepatitis: effects of hepatitis B virus on neutrophil function in vitro and in children with chronic active hepatitis

Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome

HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation

Detection of human immunodeficiency virus infection of myeloid precursors in bone marrow samples from AIDS patients

CD34+ bone marrow microvascular endothelial cells (MVEC) are consistently infected by HIV-1 in patients with AIDS: suboptimal release of IL-6 and G-CSF by infected stromal cells does not depend on release of soluble inhibitory factors

Imbalance in production of cytokines by bone marrowstromal cells following cytomegalovirus infection

Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization

Filgrastim (r-metHuG-CSF) treatment of HIVinfected patients improves neutrophil function

Heterogeneity and plasticity of T helper cells

Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis

Reversal of accelerated neutrophil apoptosis and restoration of respiratory burst activity with r-metHuG-CSF (Filgrastim therapy in patients with AIDS

T regulatory cells: immune suppression and beyond

IL-17 and Th17 Cells

Requirement of endogenous stem cell factor and granulocyte colony-stimulating factor for IL-17-mediated granulopoiesis

Evidence for a cross-talk between human neutrophils and Th17 cells

Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis

Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice

Th17 cells and HIV infection

Th17, gut, and HIV: therapeutic implications

Th17 cells, Job's syndrome and HIV: opportunities for bacterial and fungal infections

Filgrastim restores interleukin-2 production in blood from patients with advanced human immunodeficiency virus infection

A protective function for interleukin 17A in T cell-mediated intestinal inflammation

Outcome for hospitalized patients with fever and neutropenia who are infected with the human immunodeficiency virus

Human immunodeficiency virus diseaserelated neutropenia and the risk of hospitalization for bacterial infection

Clinical significance of neutropenia in patients with human immunodeficiency virus infection

Risk of bacteremia in HIV-infected person with neutropenia

Zidovudine-induced neutropenia. Are we too cautious?

Neutropenia is associated with bacteremia in patients infected with the human immunodeficiency virus

Neutropenia and bacterial infection in acquired immunodeficiency syndrome

Risk of gram-negative bacteremia during neutropenia in patients with AIDS

Estimation of the effect of neutropenia on rates of clinical bacteraemia in HIV-infected patients

Neutropenia is a risk factor for gram-negative bacillus bacteremia in human immunodeficiency virus-infected patients: results of a nested case-control study

Neutropenia in patients with HIV infection: a case control study in a cohort of 1403 patients between 1982 and 1993

Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study

Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan

Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients

Aspergillosis: from diagnosis to prevention

Invasive aspergillosis in patients with AIDS

Aspergillus species colonization and invasive disease in patients with AIDS

Invasive aspergillosis in Italian AIDS patients

Pulmonary aspergillosis and invasive disease in AIDS

Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS

Recombinant human granulocyte colonystimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection

Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine

Granulocyte-colony stimulating factor G-CSF in AIDS-patients with leukocytes less than or equal to 1.0 Â

Filgrastim (G-CSF) use is associated with prolonged survival in AIDS-patients with leukopenia and CD4 cells less than 50 x 10 6

Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection

Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial

Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis

Augmentation of leukocyte count with G-CSF in a patient with neutropenia before In-111 WBC scintigraphy

G CSF association with prolonged survival in HIV infected patients with disseminated Mycobacterium avium complex infection

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

Chemotherapy for human immunodeficiency virusassociated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy

Effects of recombinant granulocyte colonystimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL)

Economic and clinical evaluation of therapy of HIV-related non-Hodgkin's lymphoma with chemotherapy and granulocyte colony-stimulating factor (G-CSF)

Use of hematopoietic growth factors in AIDS-related malignancies

Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience

Disseminated intravascular coagulation associated with granulocyte colony-stimulating factor therapy in a child with human immunodeficiency virus infection

Probable G-CSFinduced hepatitis and pancreatitis in an HIV-seropositive patient

Granulocyte colony-stimulating factor administration: adverse events

Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudinetreated patients with AIDS and AIDS related complex, a phase I/II study

Clinical guidelines and pharmacist intervention program for HIV-infected patients requiring granulocyte colonystimulating factor therapy

Recombinant granulocyte colony-stimulating factor (rG-CSF) in HIV patients with zidovudine related neutropenia

Efficacy of granulocyte colony-stimulating factor (G-CSF) on neutropenia in zidovudine-treated patients with AIDS and ARC: a preliminary report

Effects of granulocyte-colony-stimulating factor in neutropenic AIDS-patients

Granulocyte colony-stimulating factor treatment in AIDS patients

Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients

Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection

Efficacy of recombinant granulocyte colony-stimulating factor in the long-term treatment of AIDS-related neutropenia

Growth factors and HIVinfection in children

Minimum effective dose and duration to reverse neutropenia in non-cancer patients with advanced HIV disease

Treatment of neutropenic oral ulceration in human immunodeficiency virus infection with G-CSF. Oral Surg Oral Med Oral Pathol Oral Radiol Endod

Combined therapy with zidovudine, recombinant granulocyte colony stimulating factors and erythropoietin in asymptomatic HIV patients

Increase in lymphocyte subsets following treatment of HIVassociated neutropenia with granulocyte colony-stimulating factor

Granulocyte-colony stimulating factor and erythropoietin therapy in children with human immunodeficiency virus infection

Outcomes of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus

Granulocyte colonystimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients

Rapid clearance of Mycobacterium avium from the blood of nonneutropenic AIDS patients treated with G-CSF (Filgrastim) and antimycobacterial therapy

Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients

Immunological and virological changes in antiretroviral naïve human immunodeficiency virus infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART

Granulocyte colony-stimulating factor increases CD4 + T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial

Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells

The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals

Influence of filgrastim (granulocyte colonystimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis

Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim

Stimulation of Kaposi's sarcoma-associated herpesvirus viremia during hematopoietic stem cell mobilization with filgrastim

Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin